Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is viewed favorably because relacorilant is gaining meaningful regulatory momentum in both Europe and the US, with the CHMP recommending EU approval for platinum-resistant ovarian cancer after ROSELLA showed better mPFS and mOS with a similar safety profile. The company also appears to have a credible commercial runway, supported by Lifyorli’s $47.6M first-quarter US launch sales, an established European footprint, and evidence that international ovarian cancer sales can be material, as seen with Elahere’s growth to $83M in FY25 and $88M YTD in 1H26. Fundamentally, the outlook improves as Corcept advances a potential second relacorilant approval pathway after the May 27, 2026 resubmission plan, while valuation work still implies substantial enterprise value upside at about $21.6B in one model and $12.5B in another.

Corcept Therapeutics is facing a muted outlook because Most Favored Nation pricing, announced on May 12, 2025, makes the non-U.S. launch case for Lifyorli less certain and could compress the economics of expanding into Europe. The company has not yet committed to a European launch strategy, so there is limited visibility on when, or whether, meaningful ex-U.S. revenue can be captured, and the valuation currently excludes non-US Lifyorli revenues. More broadly, the need to wait and reassess launch timing underscores execution risk and weakens the fundamental support for future growth despite the drug’s U.S. commercial potential.